Local Recurrence — Cancer Returning at the Original Site

Local recurrence refers to the reappearance of malignant cells at or immediately adjacent to the primary tumour bed following definitive treatment. Even when surgery, radiotherapy, or systemic therapies appear to eliminate all visible signs of cancer, microscopic cells can occasionally survive undetected in surrounding margins or local tissues.

Over time, these dormant or resistant microscopic cells can begin multiplying again, forming a new, detectable tumour in the same location. Local recurrence is distinct from regional recurrence, which involves nearby lymph nodes, and distant recurrence, which occurs when cancer spreads to distant organs such as the lungs, liver, or bones.

Knowing about local recurrence helps you recognise the importance of regular follow-up appointments and surveillance scans after primary treatment ends. Detecting a recurrence when it is small and confined to the original site often means it can be treated effectively, sometimes with curative intent. It allows you and your doctor to reconsider local treatment options, such as further surgery or radiotherapy, and evaluate whether systemic therapies should be adjusted to keep the disease under control and prevent further spread.

Local recurrence is typically identified through routine surveillance, physical examination, and diagnostic imaging such as ultrasound, mammography, CT, MRI, or PET scans. When an abnormal lesion is detected, a core needle or surgical biopsy is performed to obtain tissue. Pathologists examine the sample to confirm malignancy and evaluate biomarkers like ER, PR, HER2, or mismatch repair status.

Local recurrence is frequently discussed in breast cancer, where disease may recur within the treated breast or chest wall. It is also an important concept in colorectal cancer, head and neck cancers, soft tissue sarcomas, prostate cancer, and non-melanoma or melanoma skin cancers, where local margin control is critical to long-term outcomes.

Management of local recurrence depends on previous therapies received. If breast-conserving surgery was performed previously, a mastectomy may be advised; if radiation was not fully exhausted, re-irradiation might be considered. Systemic options including chemotherapy, targeted therapies, or immunotherapy are often added to treat micro-metastatic risk and regain long-term tumour control.